All trading involves risk. Contracts for Difference (CFDs) are complex instruments and may not be suitable for all investors. Please refer to Risk Disclosure and Risk Fact Sheet on Capital.com/en-sg.
Open platformOpen platform

Ionis Pharmaceuticals Q3 revenue rises 55%

By Reuters News


Overview

  • Biotech firm's Q3 revenue rose 54.8% yr/yr, driven by commercial and R&D revenue growth

  • Adjusted operating income for Q3 beat analyst expectations

  • Company lowered 2026 TRYNGOLZA sales guidance on slower-than-expected launch ramp


Outlook

  • Ionis lowers 2026 TRYNGOLZA product sales guidance to ~$50 mln

  • Company reaffirms 2026 DAWNZERA product sales guidance of $110-120 mln

  • Ionis reaffirms 2026 total revenue, operating loss and cash guidance


Result Drivers

  • DAWNZERA SALES - Co said DAWNZERA product sales were the main driver of commercial revenue growth in Q3

  • PARTNERSHIP PAYMENTS - Higher R&D revenue in Q3 was driven by payments from advancing partnered programs


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Adjusted Operating Income

Beat

$87 mln

-$199.48 mln (17 Analysts)

Q3 Adjusted Operating Expenses

$330 mln

Q3 Operating Expenses

$373 mln

Q3 Operating Income

$130 mln


Reuters Recommended Reads

  • Nov 6 - CG Oncology Q3 net loss widens on higher R&D costs

  • Nov 6 - Aligos Therapeutics Q3 net loss narrows on lower R&D costs

  • Nov 6 - UK's Immunocore Q3 loss misses estimates on higher R&D spending


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.